.svg)
John Schroeder and Jason Matuszewski Give Presentation At CAMPS 2025
Last week at CAMPS 2025, John Schroeder, CEO of Venture Medical, and Jason Matuszewski, CEO of BioStem Technology, took the stage to deliver a compelling presentation titled “Why You Should Care About Investors in the Wound Care Space.”
Last week at CAMPS 2025, John Schroeder, CEO of Venture Medical, and Jason Matuszewski, CEO of BioStem Technology, took the stage to deliver a compelling presentation titled “Why You Should Care About Investors in the Wound Care Space.”
Their talk resonated strongly with the audience, shedding light on the crucial role of investment in driving innovation, expanding access to advanced treatments, and improving patient outcomes. They highlighted key industry trends, shared real-world examples, and emphasized why funding in this sector is not just beneficial but essential for long-term advancements in wound care.
Attendees left the session with a deeper understanding of the financial landscape behind wound care innovation and how strategic investments can accelerate the development of groundbreaking therapies. The presentation was well received, sparking engaging discussions among industry professionals eager to see continued growth in the field.
As the wound care space continues to evolve, the insights from leaders like Schroeder and Matuszewski will be instrumental in shaping its future.
Stay tuned for more updates from Venture Medical as we continue to push the boundaries of what’s possible in wound care. We will be attending more conferences in the upcoming months and there will be more opportunities to hear what these thought leaders have to say about the industry.
Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio
Venture Medical, LLC, a leader in wound care solutions, today announced its acquisition of certain assets of ProgenaCare Global, LLC, a biotechnology company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix®, along with intellectual property supporting an expected future product line. Howard Walthall, former CEO of ProgenaCare, has also joined Venture Medical as Senior Vice President of Product Development.
Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market
Venture Medical, LLC, a leading provider of advanced wound care solutions, is proud to announce a strategic development and distribution agreement in principle with Plasmacure B.V., the Netherlands-basedMedTech innovator behind the revolutionary PLASOMA cold plasma system for chronic wound treatment.
.png)
Open Wound Research and Venture Medical Announce Collaboration to Advance Pressure Ulcer Research
Open Wound Research and Venture Medical, LLC have entered into a collaborative research agreement to advance the study of pressure ulcer treatment. As part of this partnership, Venture Medical has acquired extensive pressure ulcer data from Open Wound Research to evaluate the efficacy of CAMPS in comparison to standard of care (SOC) treatments.
.png)
Venture Medical Launches New Website!
We invite you to explore our brand new website
